Transcript Presentation Title Goes Here

Diabetes:
Where Are We Now?
Elaine M. Szewc, RN, BS, AALU, ALMI
Assistant Chief Medical Director
Life Underwriting
Insurance products are issued by: John Hancock Life Insurance
Company (U.S.A.), Boston, MA 02116 (not licensed in New York) and
John Hancock Life Insurance Company of New York, Valhalla, NY
10595. Insurance policies and/or associated riders and features may
not be available in all states.
© 2010 John Hancock. All rights reserved. MLINY06161013210
For agent use only. This material may not be used with the public
Overview
• According to the 2011 National Diabetes Fact Sheet (released
1/26/2011):
– 25.8 million individuals (8.3% of the population) in the U.S.
have diabetes
• 18.8 million have a diagnosis of diabetes
• 7.0 million are undiagnosed
• 1.9 million NEW cases of diabetes are diagnosed each year in
individuals over age 20
– 79 million have “pre-diabetes”
– Prevalence
• 2 million adolescents, age 12-19 have “pre-diabetes”
• 25.6 million (11.3 %) over age 20
• 10.9 million (26.9%) over age 65
Source: http://www.diabetes.org
2 of 53
For agent use only. This material may not be used with the public.
Adults with Diagnosed Diabetes, US,
1980--2009
www.cdc.gov/diabetes/statistics/prev/national/figadults.htm
3 of 53
For agent use only. This material may not be used with the public.
Overview (cont’d)
• Morbidity and Mortality:
– 7th leading cause of death listed on U.S. death certificates in 2007
as “underlying cause of death”
– In 2004, heart disease was noted on 68% of diabetes-related
death certificates among individuals 65 and up, while stroke was
noted on 16%
• Diabetics with heart disease have 2 to 4 times higher death
rates than adults without diabetes
• Risk for stroke is 2 to 4 times higher among diabetics
– Diabetes is the leading cause of new cases of blindness each year,
with 12,000 to 24,000 new cases of diabetic retinopathy
Source: http://www.diabetes.org
4 of 53
For agent use only. This material may not be used with the public.
Overview (cont’d)
• Morbidity and Mortality (cont’d):
– Diabetes is the leading cause of kidney failure, accounting for
44% of new cases in 2008
– 60 to 70% of individuals with diabetes will have mild to severe
peripheral neuropathy as a result of their diabetes
– 60% of non-traumatic lower-limb amputations occur in individuals
with diabetes
Source: http://www.diabetes.org
5 of 53
For agent use only. This material may not be used with the public.
IGT/IFG/Pre-Diabetes – Defined
• Impaired glucose tolerance (IGT)/impaired fasting glucose (IFG) is now
known as pre-diabetes
– Pre-diabetes is the state that occurs when blood glucose levels are
higher than normal but not high enough for a diagnosis of diabetes
– Just a name change
• Clearer explanation of what it means to have higher than normal
blood glucose levels
• Individuals with pre-diabetes have 1.5 fold risk of CAD
• Individuals with diabetes have 2 to 4 fold risk of CAD
– Individuals with pre-diabetes can delay or prevent onset of diabetes
through lifestyle changes
• 25% of individuals will progress to diabetes over 3 to 5 years
• Those with family history, obesity are more likely to progress
more rapidly
6 of 53
For agent use only. This material may not be used with the public.
IGT/IFG/Pre-Diabetes – Defined (cont’d)
• Undiagnosed diabetes can cause progressive microvascular disease
• Approximately 20% of newly diagnosed patients with Type 2 DM have
diabetic retinopathy and 10% have nephropathy (microvascular
complications)
• IGT/IFG/pre-diabetes are NOT clinical entities, but rather risk factors
for diabetes as well as cardiovascular disease
Source: http://www.diabetes.org
7 of 53
For agent use only. This material may not be used with the public.
Diabetes - Defined
• 1997 – the ADA refined terms to describe diabetes
– Encouraged use of Type 1 or Type 2 and discouraged use of
terms such as juvenile onset, insulin-dependent, noninsulin dependent, mature onset or adult onset
• 2003 – criteria for fasting plasma glucose level to define
impaired fasting glucose (IFG) was lowered
– Lowering level impacts many older age individuals
– Allows early diagnosis and potential risk factor
modifications to prevent micro and macrovascular risk
• 2010 – added A1c to diagnostic criteria
Source: Up-to-date, Diagnosis of diabetes mellitus, McCulloch David, updated August 2009
8 of 53
For agent use only. This material may not be used with the public.
Diabetes – Defined (cont’d)
• Criteria for the diagnosis of diabetes mellitus, 2010
– A1c > 6.5%
OR
– FPG 126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric
intake for at least 8 hours
OR
– 2-h plasma glucose 200mg/dl (11.1 mmol/l) during an OGTT. The
test should be performed as described by the World Health
Organization, using a glucose load containing the equivalent of
75 g anhydrous glucose dissolved in water
OR
– Symptoms of diabetes and a random plasma glucose 200 mg/dl
(11.1 mmol/l). Casual is defined as any time of day without
regard to time since last meal. The classic symptoms of diabetes
include polyuria, polydipsia, and unexplained weight loss
Source: Up-to-date, Diagnosis of diabetes mellitus, McCulloch David, updated June 2011
9 of 53
For agent use only. This material may not be used with the public.
Diabetes – Defined (cont’d)
• Categories of increased risk for diabetes:
– Impaired fasting glucose (IFG)
FPG > 100-125 mg/dL
– Impaired glucose tolerance (IGT)
2 hour PG (75g OGTT) > 140 – 199 mg/dL
– A1c 5.7 – 6.4%
Normal fasting glucose < 100 mg/dL
Source: Up-to-date, Diagnosis of diabetes mellitus, McCulloch David, updated June 2011
10 of 53
For agent use only. This material may not be used with the public.
ADA Guidelines – IGT/IFG
• Goal of intervention in individuals with IGT or IFG includes prevention
of diabetes and associated risk of cardiovascular disease
• Lifestyle modifications are the primary intervention
• Specific goals include:
– Moderate weight loss (5 – 10% of body weight)
– Moderate intensity exercise (30 minutes daily)
– Smoking cessation
• Pharmacologic agents (metformin) have demonstrated some ability
to prevent or delay diabetes
Source: Up-To-Date, Prediction and prevention of type 2 diabetes mellitus, McCulloch
David K MD, Robertson R Paul MD; updated June 2009
11 of 53
For agent use only. This material may not be used with the public.
ADA Treatment -- Diabetes
• Primary goal in treatment of diabetes is glycemic control (~ 7% for
A1C) to reduce microvascular (retinopathy and nephropathy), and
neuropathic complications, as well as macrovascular (cardiovascular,
cerebrovascular) risk reduction
– Less stringent control in subset of individuals with history of
severe hypoglycemia, limited life expectancy (< 5 years),
advanced microvascular or macrovascular complications and
extensive co-morbid conditions
– Risk factor modification to further reduce cardiovascular morbidity
and risk of future cardiac events
12 of 53
For agent use only. This material may not be used with the public.
Diabetes and CAD
• Compared to individuals without diabetes, those with diabetes have a
higher prevalence of CAD, a greater extent of coronary ischemia and
are more likely to have a MI, and silent ischemia
Source: Up-To-Date, Prevalence of and risk factors for coronary heart disease
in diabetes mellitus, Nesto, Richard W. MD; updated September 2009
13 of 53
For agent use only. This material may not be used with the public.
Diabetes and CAD (cont’d)
• Based on results from Framingham Heart Study and MRFIT, diabetes
remains a major independent cardiovascular risk factor even when
adjusting for advancing age, hypertension, smoking,
hypercholesterolemia and LVH
– Presence of diabetes doubled the age-adjusted risk for
cardiovascular disease in men and tripled it in women
– Framingham study revealed in Type I diabetics that after age 30,
CHD mortality increased rapidly
• Cumulative CHD mortality was 35 % by age 55, compared to
8% for non-diabetic men
14 of 53
For agent use only. This material may not be used with the public.
Diabetes and CAD (cont’d)
• TAMI trial provided cath data which revealed the diabetic patients
had a significantly higher incidence of multivessel disease (66%
versus 46%) and a greater number of diseased vessels then the
non-diabetics
– Multivessel disease is also common in asymptomatic individuals
with Type 2 diabetes, particularly those with two or more coronary
risk factors other then diabetes
– Association between extent of coronary disease and the degree of
glycemic control
15 of 53
For agent use only. This material may not be used with the public.
Diabetes and CAD (cont’d)
• ARIC study in US, large population based study revealed Type 2
diabetics without a prior infarction were at the same risk for MI (20%
versus 19%) and coronary mortality (15% versus 16%) as
non-diabetics with a prior MI
• Diabetics are more likely to experience a complication associated with
an MI, including post infarction angina and heart failure
16 of 53
For agent use only. This material may not be used with the public.
17 of 53
For agent use only. This material may not be used with the public.
Diabetes and CAD (cont’d)
• Individuals with diabetes comprise as much as 25-30% of those
individuals who undergo revascularization
• PCI versus CABG
– Diabetics having PCI have increased rates of both restenosis and
progression of disease compared to non-diabetics
• Drug-eluting stents (DES) are now used in preference to bare
metal stents (BMS) due to marked reductions in incidence of
restenosis
– Long-term prognosis after CABG in patients with diabetes is worse
then in non-diabetics
– Future of PCI with DES versus CABG?
Source: Up-To-Date, Coronary artery revascularization inpatients with diabetes
mellitus, Nesto, Richard w. MD, updated June 2009
18 of 53
For agent use only. This material may not be used with the public.
Diabetes and CAD (cont’d)
• BUT…………..
– Improving trends over the last 50 years with incidence of
cardiovascular disease declining
– Framingham Heart Study
• 49% decline in cardiovascular events (MI, CAD death, stroke)
in diabetics
• 35% decline in cardiovascular events in non-diabetics
• BUT……………
– Diabetes was still associated with a two-fold increase in risk
19 of 53
For agent use only. This material may not be used with the public.
Diabetes and Hypertension
• UKPDS (United Kingdom Prospective Diabetes Study) noted at
nine-year follow-up:
– Each 10 mmHg reduction in mean systolic pressure was
associated with a 12% reduction in any complication related to
diabetes (including cardiovascular disease)
• Lowest risk occurred at systolic pressure < 120 mmHg
– Similar relationship noted with fatal or non-fatal MI as incidence
fell from 33.1% per 1,000 patient years at systolic pressure
>160 mmHg to 18.4% per 1,000 patient years at systolic
pressure <120 mmHg
• Aggressive antihypertensive therapy with recommended goal blood
pressure <130/80 mmHg
20 of 53
For agent use only. This material may not be used with the public.
21 of 53
For agent use only. This material may not be used with the public.
Diabetes and Dyslipidemia
• With diabetes being considered a CHD equivalent
– Goal LDL is <100 mg/dL in individuals without overt CAD – in
those with CAD goal LDL is < 70 mg/dL
– Triglyercide levels <150 mg/dL
– HDL levels >40 mg/dL for men and >50 mg/dL for women
22 of 53
For agent use only. This material may not be used with the public.
Diabetes and Microalbuminuria
• Microalbuminuria is defined as persistent urinary albumin excretion
between 30 and 300 mg/day
– Microalbuminuria is the earliest clinical manifestation of diabetic
nephropathy
– Associated with an increase risk of cardiovascular disease in both
diabetic and non-diabetic patients
– Relative risk for all cause mortality was 1.9 compared to
individuals with no evidence for microalbuminuria
– Relative risk for cardiovascular and coronary heart disease
mortality was 2.0 and 2.3 compared to individuals with no
evidence for microalbuminuria
• Macroalbuminuria is defined as albumin excretion above 300 mg/day
Source: Up-To-Date, Microabluminuria in type 2 diabetes mellitus, McCulloch, David
K. MD, Barkris, George L. MD; updated August 2009
23 of 53
For agent use only. This material may not be used with the public.
Diabetes and Microalbuminuria (cont’d)
• In individuals with Type 1 diabetes, the reported prevalence of
microalbuminuria at 10 years is between 25-40%
• Prevalence of microalbuminuria in Type 2 diabetes, varies with
ethnicity, being higher in Asians and Hispanics than in whites (43%
versus 33% in whites)
• Prevalence of microalbuminuria in elderly individuals with Type 2
diabetes is higher (? Due to hypertension, coronary disease etc)
Source: Up-To-Date, Microalbuminuria in type 2 diabetes mellitus, McCulloch, David
K.MD, Bakris, George L. MD; updated August 2009
24 of 53
For agent use only. This material may not be used with the public.
Diabetes and Microalbuminuria (cont’d)
• HOPE (Heart Outcomes Prevention Evaluation) trial
– 9,000 participants
– Presence of microalbuminuria was associated with an increased
relative risk of primary aggregate end point (myocardial
infarction, stroke, or cardiovascular death) in those with and
without diabetes (1.97 and 1.61 respectively)
– Risk of an adverse cardiovascular event increased progressively
with increased absolute levels of microalbuminuria
25 of 53
For agent use only. This material may not be used with the public.
Diabetes and Microalbuminuria (cont’d)
• Rate of progression to macroalbuminuria is approximately 2.5% in
Type 1 and 2.8% per year in Type 2
– Higher baseline levels of albuminuria
– Poor glycemic control
– Inadequate blood pressure control
– Smoking
26 of 53
For agent use only. This material may not be used with the public.
Diabetes and Microalbuminuria (cont’d)
• Regression to normoalbuminuria
– Short duration of microalbuminuria
– Better glycemic control (Hgb A1C < 7%)
– Systolic blood pressure <129 mmHg
– Use of ACE inhibitors or angiotensin II receptor blockers
• Regression or at least 50% reduction in albumin excretion compared
to no reduction was associated with significant reductions in death
from and hospitalization for renal and cardiovascular events
(adjusted risk 0.41)
Source: Up-To-Date, Microalbuminuria in type 2 diabetes mellitus, McCulloch,
David K.MD, Bakris, George L. MD; updated August 2009
27 of 53
For agent use only. This material may not be used with the public.
Diabetes and Microalbuminuria (cont’d)
• Focus of treatment:
– Glycemic control
– Blood pressure control
• Angiotension converting enzyme (ACE) inhibitors
• Angiotensin II receptor blockers (ARBs)
• Calcium channel blockers – primarily diltiazem and verapamil
for the antiproteinuric effect
• Goal is to reduce both microalbuminuria and prevent progression to
macroalbuminuria
28 of 53
For agent use only. This material may not be used with the public.
Diabetes and Elderly Adults
• Prevalence of Type 2 diabetes continues to increase with
increasing age
– 1.4% in ages 25-44
– 3.6% in ages 45-54
– 7.8% in ages 55-64
– Over 10% in ages >65
• Prevalence of Type 2 diabetes is likely to further increase with the
new diagnostic criteria and current recommendations to screen
individuals over age 45 once every three years
Source: Up-To-Date, Treatment of diabetes mellitus in elderly adults, McCulloch,
David K. MD, Munshi, Medha, MD, updated June 2009
29 of 53
For agent use only. This material may not be used with the public.
Diabetes and Elderly Adults (cont’d)
• According to ADA, goals for glycemic control as well as risk factor
management in the elderly adult should be based upon the
overall health
– Target A1C in a fit elderly individual with life expectancy >5 years,
should be 7.0 to 8.0%
– Somewhat higher if life expectancy is less or if multiple medical
and functional co-morbidities
30 of 53
For agent use only. This material may not be used with the public.
Diabetes and Elderly Adults (cont’d)
• Managing elderly adults with diabetes and co-existing medical
conditions is a challenge
– Hypoglycemia & Hyperglycemia
• Cognition difficulties
• Increased risk for falls and injuries
• Hypoglycemic episodes increase the risk of adverse
cardiovascular events
– Drug interactions from poly pharmacy
• Start slow and go slow with medication changes or additions
– Natural history of diabetic retinopathy may differ in elderly adults
• Macular degeneration
31 of 53
For agent use only. This material may not be used with the public.
Diabetes and Elderly Adults (cont’d)
• Diabetic nephropathy
– Renal artery stenosis
• Diabetic neuropathy
– Vascular conditions
– Neurologic conditions
• Cardiovascular risk reduction
– Maintain risk factor modifications
32 of 53
For agent use only. This material may not be used with the public.
What has Changed in Underwriting Diabetes?
• Type I diabetic
– Life insurance coverage available!
– Insulin Pumps
– Pancreatic & islet transplantation
• Type II diabetic
– Increased prevalence
– Use of insulin to control blood glucose
– Changing focus of control, more emphasis on
cardiovascular risk factor modifications
33 of 53
For agent use only. This material may not be used with the public.
What’s New, What’s Pending
• Insulin inhalers in clinical trials
– Afrezza – ultra rapid acting inhaled insulin, absorbed
through lungs, peaks 12 to 14 minutes after inhaled –
short acting (3 hours) used at meal time to buffer the
“glucose spikes”
– Oral-lyn – rapid acting inhaled insulin, sprayed in
mouth absorbed through buccal mucosa, used at meal
time
• PH20 – new ultrafast insulin analog – Phase 2 trials
• Juvisnyc FDA approval 10/7/11 – combines Sitagliptin
(Januvia) & simvastatin to treat high cholesterol and Type 2
diabetes
• Insulin degludec – awaiting FDA approval -- long acting
insulin, clinical trials have favorable results in lowering
frequency of hypoglycemia especially during night
34 of 53
For agent use only. This material may not be used with the public.
What’s New, What’s Pending (cont’d)
• Awaiting FDA approval for clinical trials – wireless insulin
delivery system that functions like a human pancreas –
continuous glucose monitor, programmable insulin pump,
computer algorithm that calculates how much insulin is need
and when needed
• Pending FDA approval – Iglucose, wirelessly collects, stores
and transmits glucose readings from select glucose monitors
to a secure HIPPA compliant database that can be sent to your
healthcare provider
• FDA approved iPro2 is a 3 day evaluation system for
continuous glucose monitoring – glucose sensor inserted into
patients skin, after 3 days sensor removed – helps identify
nocturnal hypoglycemia or postprandial hyperglycemia
• The list goes on…………………………
35 of 53
For agent use only. This material may not be used with the public.
Controlling Diabetes
• Disability and premature death are not inevitable consequence
of diabetes
• Physical activity, diet, medications can control effects of
diabetes
• Reducing A1c by 1% can reduce risk of eye, kidney,
retinopathy by 40%
• Controlling blood pressure can reduce risk of heart disease and
stroke by 33 – 50%
• Improving LDL cholesterol can reduce cardiovascular
complications by 20 – 50%
• Laser therapy for diabetic retinopathy can reduce risk of
blindness by 50 – 60%
• Foot care programs can reduce amputation rates by 45-85%
www.cdc.gov/chronicdisease/resources/publications/AAG/ddt.htm
36 of 53
For agent use only. This material may not be used with the public.
The Many Faces of Diabetes
Can you identify
who has diabetes?
Who has Type I,
Type II?
Who has multiple
complications?
37 of 53
For agent use only. This material may not be used with the public.
Diabetes Case Studies
So, is diabetes with a little of this and a little of that
really all that bad?
38 of 53
For agent use only. This material may not be used with the public.
Case Study #1
• 82 year-old female, Non-Smoker, informal $120,000
• Exam:
– 5’3”, 192 lbs, 164/87 (exam average)
– Type 2 DM, diet controlled
– HBP on meds
–
–
–
–
–
39 of 53
^ lipids on meds
Neuropathy on neurontin
DWR 10/10
GUG 8 seconds
Drives, socially active with senior center, mows her own lawn
For agent use only. This material may not be used with the public.
Case Study #1 (cont’d)
• Labs:
– Glucose 81 mg/dL
– Fructosamine 2mmol/L
– BUN 19
– Creatinine 0.7
– Cholesterol 184 – ratio 4.6
– proBNP 110 pg/mL
• Urine:
– Protein 7 mg
– p/c ratio 0.12 mg/mg cr
– Hemogloblin screen (+)
– WBC 3
– RBC 5
40 of 53
For agent use only. This material may not be used with the public.
Case Study #1 (cont’d)
• APS:
– Diabetes for last 5+ years, diet controlled
– A1C in aps ranges from 6.0 to 7.1 (2/10 labs)
– Hx of UTI in 3/09 and again in 2/10
– Random urine MA in 3/09 35 ug/mL (normal to 17)
– Serum creatinine range from 0.6 to 0.75 mg/dL
– eGFR >59
– Blood pressure average in APS was 120/80 over the last three years
41 of 53
For agent use only. This material may not be used with the public.
Case Study #1 (cont’d)
• Additional urine #1
–
–
–
–
–
Protein 2mg
Creatinine 8.2 mg/dL
p/c ratio 0.24 mg/mg cr
Hemogloblin screen (-)
MA 0.7 mg/dL (normal
<3)
– Malb/creat ratio
85.3 mg/Gcre (normal
<30)
• Additional urine #2
– Protein 2mg
– Creatinine 5.7 mg/dL
– p/c ratio 0.35 mg/mg cr
– Hemogloblin screen (-)
– MA 0.6 mg/dL
– Malb/creat ratio
105.2 mg/Gcre
• Opinion?
42 of 53
For agent use only. This material may not be used with the public.
Case Study #1 (cont’d)
• Opinion?
– (+) urine MA with good KFT’s, good blood pressure
control
– Mild substandard to standard
43 of 53
For agent use only. This material may not be used with the public.
Case Study #2
• 49 year-old male, Non-Smoker, formal $750,000
• Exam:
– 6’2”, 200 lbs
– DM since age 24
– HBP
– Meds – novolog, lantus, caduet, avalide
44 of 53
For agent use only. This material may not be used with the public.
Case Study #2 (cont’d)
• Labs:
– Glucose 117 mg/dL
– Fructosamine 2.94 mmol/L
– A1C 9.2%
– BUN 16 mg/dL
– Creatinine 1.17 mg/dL
• Urine:
– Glucose 0.053 g/dL
– Protein 7 mg/dL
– Creatinine 62 mg/dL
– MA 4.3 mg/dL
– MA/creatinine ratio 69.354 mg/Gcre
45 of 53
For agent use only. This material may not be used with the public.
Case Study #2 (cont’d)
• APS:
– LOV 9/09, c/o pain tingling numbness bilateral feet
– A1C difficult to control, occasional hypoglycemia
– Hx syncopal episode secondary to hypoglycemia
– 5/09 episode hypoglycemia
– A1c trends
•
•
•
•
09/09
05/09
12/08
07/08
8.5
8.5
9.0
8.9
• Opinion?
46 of 53
For agent use only. This material may not be used with the public.
Case Study #2 (cont’d)
• Opinion?
– Type I diabetic
– Fair to poor control
– Syncopal episode due to hypoglycemia
– Neuropathy
– Microalbuminuria
– Decline
47 of 53
For agent use only. This material may not be used with the public.
Case Study #3
• 75 year-old male, Non-Smoker, informal $5,000,000
• Exam:
– 5’10’’, 185 lbs, 124/72
– HBP on meds
– ^ lipids on meds
– Type 2 DM, diagnosed 2 years ago, metformin
– CABG 10 years ago to two vessels
48 of 53
For agent use only. This material may not be used with the public.
Case Study #3 (cont’d)
• Labs:
– Glucose 116
– A1C 6.1
– Cholesterol 184, ratio 3.3
• Urine:
– MA 2.1
49 of 53
For agent use only. This material may not be used with the public.
Case Study #3 (cont’d)
• APS:
– 2/00 cath due to abnormal perfusion study to evaluate chest pain
• LM 40% distally
• RCA 80%
• Circumflex 50% with good collateral fill
– 3/00 CABG with LIMA to proximal LAD, sapphenous vein graft to
mid RCA
– Serial stress echo’s, last in 1/10 – exercised 9 min, achieved 10
METS, normal blood pressure response to exercise, normal wall
motion, no evidence for ischemia, EF 60%
50 of 53
For agent use only. This material may not be used with the public.
Case Study #3 (cont’d)
• APS (cont’d):
– 2008 diagnosed with Type 2 diabetes, placed on metformin
– A1C trends have been in the 6.2 to 7.5 range with the last A1C
in 1/10 of 6.8
– Exercises 3x per week at senior center
• Opinion?
51 of 53
For agent use only. This material may not be used with the public.
Case Study #3 (cont’d)
• Opinion?
– Older age for onset of diabetes
– Good control of diabetes
– CABG history ten years prior
– Last stress test 2010 with good exercise capacity at 9 min, good
EF, negative for ischemia
– Mild substandard to standard
52 of 53
For agent use only. This material may not be used with the public.
Questions?
53 of 53
For agent use only. This material may not be used with the public.